



## Product Information

### Roar MTP Activity Assay Kit, 100 assays

Catalog No. RB-MTP


U.S. Pat. Nos. 5,585,235; 5,618,683; 5,770,355

<b>Assay Method:</b>	Fluorometric
<b>Number of Assays:</b>	100 assays in 200 $\mu$ l total assay volume
<b>Kit Contents:</b>	Donor particle: 400 $\mu$ l Acceptor particle: 400 $\mu$ l Assay buffer: 20 ml
<b>Storage and Handling:</b>	Store kit components at 4°C. If stored properly, components are stable for up to 1 year. DO NOT FREEZE.
<b>Instrumentation:</b>	Fluorescence spectrophotometer Excitation: 465 nm / Emission: 535 nm.

### Introduction

Microsomal triglyceride transfer protein (MTP), a membrane-bound protein present in the liver, plays an important role in the assembly and secretion of very low density lipoprotein (VLDL).

The **Roar MTP Activity Assay Kit** is a sensitive, homogeneous fluorometric assay useful for continuous measurement of MTP activity in cell lysate or tissue homogenate.



The **Roar MTP Activity Assay Kit** includes proprietary substrates that enable the detection of MTP-mediated transfer of neutral lipid. The transfer activity results in an increase in fluorescence intensity. DMSO tolerance is 10% (v/v) and the assay components are stable for up to one year.

## Materials Required, But Not Supplied

Fluorimeter with appropriate wavelength capabilities (Ex: 465 nm; Em: 535 nm)

37°C water bath / incubator

Adhesive microplate sealers

MTP source: HepG2 cell homogenate or partially purified MTP (Roar #RB-HLV)

Homogenization buffer (for preparation of HepG2 cells): 150 mM NaCl, 10 mM Tris, 1 mM EDTA, pH 7.4, 0.5 mM PMSF and 20 µg/ml leupeptin.

## Assay Method

1. Combine 4 µl of donor particle and 4 µl of acceptor particle with MTP source in 0.2 ml total volume with assay buffer. Prepare a blank that contains 4 µl of donor particle and 4 µl of acceptor particle in 200 µl total volume of assay buffer.
2. Incubate for 3 - 6 hours (depending upon the specific activity of your MTP source) at 37°C.
3. Measure the increase in fluorescence of samples using a fluorimeter (excitation: 465 nm; emission: 535 nm). Determine the fluorescence intensity transferred in the samples by subtracting the blank fluorescence intensity from each sample.

### Notes:

Sample volumes may need to be adjusted depending on the specific activity of the MTP source in your assay. For samples with low activity, decrease the buffer volume and increase the volume of your sample in the assay. Alternatively, microplates containing samples may be incubated overnight at 25°C. MTP remains active at 25°C.

A heat-killed sample may be prepared in sealed microtubes at 56°C for ~5 minutes to inactivate the protein. Cool the microtube and spin down any condensation.

Sigma supplies the Pfizer MTP inhibitor CP-346086 (Sigma #PZ0103) - see below for instructions on validating this assay with the inhibitor.

## Assay Standardization

1. The concentration of the fluorescent substrate is printed on the label of the donor particle vial. The standard curve to derive the relationship between fluorescence intensity transferred and moles of substrate transferred is generated by dispersing the donor particle in isopropanol (IPA). Use spectrally pure isopropanol (HPLC grade or better) as the solvent. There should not be any background fluorescence when isopropanol alone is read.
2. Prepare six test tubes labeled 'T0' to 'T5' each containing 1ml isopropanol, adding an additional 1 ml of isopropanol to 'T5'.
3. Pipette 5 µl donor particle to the test tube labeled 'T5', thoroughly mix (vortex) to adequately disperse the donor particle in the isopropanol.
4. Serially dilute from 'T5' to 'T1' and read the fluorescence intensity (EX 465 / EM 535) of the samples from tubes 'T0' to 'T5'.
5. Perform a linear regression using the fluorescence intensity reads at each concentration of the standard curve and calculate the pmoles transferred in your assay.

## Protocol for Preparing HepG2 Cell Homogenate

1. Grow HepG2 cells in 75 cm<sup>2</sup> T-flasks until confluent.
2. Suspend the cells from 6 flasks in a total of 5 ml of homogenization buffer (approximate protein concentration will be 10 mg/ml).
3. Sonicate the suspension on ice with five 5-second bursts in a 550W sonicator (power setting: 4) fitted with a microtip.
4. Use 100 µg of homogenate protein in the RB-MTP activity assay.

### Homogenization Buffer

To 100 ml of 10mM Tris / 150 mM NaCl / 1mM EDTA, pH 7.4, add 0.5 ml of 100 mM PMSF (Sigma #P7626) in ethanol and 2 ml of 1mg/ml leupeptin (Sigma #L2884) in Tris-saline.


**Notes:** It is not necessary to spin down cell debris to make a low-speed supernatant, nor is it necessary to partially purify membranes to assay MTP activity.

## Assay Validation with MTP Inhibitor CP-346086 (Sigma #PZ0103)

Purified MTP must be used with CP-346086. In the protocol below, MTP was purified from rat liver microsomes.

Prepare: 50 ml 100 mM tris / 100 mM KCl / 10 mM MgCl<sub>2</sub> / pH 7.4  
0.54% deoxycholate in 50 mM tris pH 7.4  
100 mM tris / 1.5 M NaCl / 10 mM EDTA pH 7.4 (this is 10x assay buffer)  
1% BSA (not fatty acid free) in assay buffer  
Chill buffers and rotor

1. Thaw 1 tube of rat liver microsomes (0.5 ml / total protein=20 mg/ml) and dilute to 3.5 mg/ml with 100 mM tris / 100 mM KCl / 10 mM MgCl<sub>2</sub> / pH 7.4 so that the resulting microsome solution is 50 mM tris / 50 mM KCl / 5 mM MgCl<sub>2</sub> at 3.5 mg/ml total protein. For example, take 1.429 ml of 100 mM tris / 100 mM KCl / 10 mM MgCl<sub>2</sub> / pH 7.4 buffer and mix with 0.929 ml distilled water plus 0.5 ml microsomes.
2. Add 0.1 x volume of deoxycholate solution while vortexing and keep on ice. For example, add 3 x 95 µl in separate steps while vortexing and chilling.
3. Incubate for 30 minutes on ice.
4. Centrifuge at 105,000 x g for 75 minutes.
5. Recover supernatant and discard pellet.
6. Add 0.1 volumes of 10x assay buffer (100 mM tris / 1.5 M NaCl / 10 mM EDTA pH 7.4)
7. Use directly in the assay with CP-346086. The final protein concentration was 1.65 mg/ml.



## Assay Validation

1. Dissolve CP-346086 in DMSO at the appropriate concentrations. For example, compound dilutions may be prepared at 5.5, 1.11, 0.55, 0.111 and 0.011  $\mu\text{M}$ . Addition of 1  $\mu\text{l}$  of each dilution to 100  $\mu\text{l}$  of assay volume will give a range of inhibitor at: 55, 11.1, 5.5, 1.11 and 0.111 nM.
2. Pre-mix assay buffer / donor / acceptor and BSA to give 0.1% final concentration of BSA and use a final assay volume of 100  $\mu\text{l}$ . For example, use 2  $\mu\text{l}$  of donor, 2  $\mu\text{l}$  of acceptor 10  $\mu\text{l}$  of 1% BSA and 80  $\mu\text{l}$  of assay buffer per assay.
3. Pipet the mix into the wells of a microplate.
4. Add 1 $\mu\text{l}$  of each dilution of CP-346086 to the wells and mix with a pipet.
5. Add 5  $\mu\text{l}$  (8.25  $\mu\text{g}$  protein) of purified MTP and incubate at 37°C for 60 minutes.
6. Read the plate at excitation 465 nm and 535 nm emission.

## Assay Results

Raw FIU			CP-346086 (nM)
1363	1488	1392	55.000
1519	1517	1485	11.100
1632	1543	1639	5.500
1855	1877	1849	1.110
1887	1891	1858	0.55
2008	1978	1890	0.110
1878	1931	1952	0.000
1426	1571	1389	Blank

## Technical Tips

- Donor and acceptor may be mixed with buffer and dispensed as one step.
- Results from duplicate samples should be tight. Variability indicates evaporation, inaccurate pipetting or incomplete mixing of assay components.
- Microplates containing samples may be incubated overnight at 25°C for more convenient reading schedules. MTP remains active at 25°C.
- Fluorescent assays are highly sensitive and will respond to slight changes in assay volume - BE SURE TO CAP TUBES.
- Microplates must be compatible with fluorescent assays. Some clear plates contain fluorescent plastic. We recommend black microplates (top-reading plate readers only) such as these: Thermo Scientific, black, U-bottom (Thermo #7205 or #7005).
- The filter must be within specifications. An excitation filter of 485 nm with a 20 nm bandwidth may NOT be used. This filter will incompletely excite the label and the standard curve will appear to work, but protein activity results will be low.

## Related Product

MTP, partially purified, human (Roar #RB-HLV), Unit size: 0.5 ml at 20 mg/ml.

**For Research Use Only. Not for Diagnostic or Therapeutic Purposes.**

---

**Roar Biomedical, Inc.**, Audubon Biomedical Center, 3960 Broadway, New York, NY 10032 USA  
Tel: +1 (212) 280-2983 ▪ Fax: +1 (212) 280-2968 ▪ info@roarbiomedical.com ▪ www.roarbiomedical.com

This product is the subject of U.S. Pat. Nos. 5,585,235; 5,618,683; 5,770,355 owned by Roar Biomedical, Inc.  
©1998-2014 Roar Biomedical, Inc. All rights reserved. This information is subject to change without notice.

## RB-MTP Cited References

### Roar MTP Activity Assay Kit

1. Satılmış B, Kayhan B, Güldür T. Effects of reciprocal interactions between various dietary fats and circadian phases on postprandial hyperlipidemia in rats. *Biol Rhythm Res.* **2018**;49(1):77-91.
2. Singh RK, Lui E, Wright D, Taylor A, Bakovic M. Alcohol extract of north american ginseng (*panax quinquefolius*) reduces fatty liver, dyslipidemia, and other complications of metabolic syndrome in a mouse model. *Can J Physiol Pharmacol.* **2017**;95(9):1046-1057.
3. Murakami S, Fujita M, Nakamura M, et al. Taurine ameliorates cholesterol metabolism by stimulating bile acid production in high- cholesterol- fed rats. *Clinical and Experimental Pharmacology and Physiology.* **2016**;43(3):372-378.
4. Rösch K, Kwiatkowski M, Hofmann S, et al. Quantitative lipid droplet proteome analysis identifies annexin A3 as a cofactor for HCV particle production. *Cell Reports.* **2016**;16:3219-3231.
5. Gong Z, Su K, Cui L, et al. Central effects of humanin on hepatic triglyceride secretion. *American Journal of Physiology - Endocrinology and Metabolism.* **2015**;309(3):E283-E292. doi: 10.1152/ajpendo.00043.2015.
6. Nozaki Y, Fujita K, Wada K, et al. Deficiency of iNOS-derived NO accelerates lipid accumulation-independent liver fibrosis in non-alcoholic steatohepatitis mouse model. *BMC Gastroenterology.* **2015**;15(42).
7. Nozaki Y, Fujita K, Wada K, et al. Deficiency of eNOS exacerbates early-stage NAFLD pathogenesis by changing the fat distribution. *BMC Gastroenterol.* **2015**;15(177).
8. Wang S, Park S, Kodali VK, et al. Identification of protein disulfide isomerase 1 as a key isomerase for disulfide bond formation in apolipoprotein B100. *Mol Biol Cell.* **2015**;26(4):594-604.
9. Cruz-Garcia L, Schlegel A. Lxr-driven enterocyte lipid droplet formation delays transport of ingested lipids. *J Lipid Res.* **2014**;55(9):1944-1958.
10. Li X, Li Y, Yang W, et al. SREBP-1c overexpression induces triglycerides accumulation through increasing lipid synthesis and decreasing lipid oxidation and VLDL assembly in bovine hepatocytes. *J Steroid Biochem Mol Biol.* **2014**;143(0):174-182.
11. Wang X, Sugimoto K, Fujisawa T, et al. Novel effect of ezetimibe to inhibit the development of non-alcoholic fatty liver disease in fatty liver shionogi mouse. *Hepatology Research.* **2014**;44(1):102-113.
12. Cheng YL, Lan KH, Lee WP, et al. Amiodarone inhibits the entry and assembly steps of hepatitis C virus life cycle. *Clin Sci (Lond).* **2013**;125(9):439-448.
13. Frochot V, Alqub M, Cattin AL, et al. The transcription factor HNF-4 $\alpha$ : A key factor of the intestinal uptake of fatty acids in mouse. *American Journal of Physiology-Gastrointestinal and Liver Physiology.* **2012**;302(11):G1253-G1263.
14. Jaschke A, Chung B, Hesse D, et al. The GTPase ARFRP1 controls the lipidation of chylomicrons in the golgi of the intestinal epithelium. *Hum Mol Genet.* **2012**;21(14):3128-3142.
15. Massart J, Robin M, Noury F, et al. Pentoxifylline aggravates fatty liver in obese and diabetic ob/ob mice by increasing intestinal glucose absorption and activating hepatic lipogenesis. *Br J Pharmacol.* **2012**;165(5):1361-1374.
16. Singh RK, Fullerton MD, Vine D, Bakovic M. Mechanism of hypertriglyceridemia in CTP: Phosphoethanolamine cytidylyltransferase-deficient mice. *J Lipid Res.* **2012**;53(9):1811-1822.
17. Zhang B, Xue C, Hu X, et al. Dietary sea cucumber cerebroside alleviates orotic acid-induced excess hepatic adipogenesis in rats. *Lipids in Health and Disease.* **2012**;11(1):48.
18. Amigo L, Husche C, Zanlungo S, et al. Cholecystectomy increases hepatic triglyceride content and very-low-density lipoproteins production in mice. *Liver International.* **2011**;31(1):52-64.
19. Goldwasser J, Cohen PY, Lin W, et al. Naringenin inhibits the assembly and long-term production of infectious hepatitis C virus particles through a PPAR-mediated mechanism. *J Hepatol.* **2011**;55(5):963-971.
20. Harris C, Herker E, Farese RV, Ott M. The hepatitis C virus core protein decreases lipid droplet turnover: A mechanism for core-induced steatosis. *J Biol Chem.* **2011**;286(49):42615-42625.
21. Banerjee A, Meyer K, Mazumdar B, Ray RB, Ray R. Hepatitis C virus differentially modulates activation of forkhead transcription factors and insulin-induced metabolic gene expression. *J Virol.* **2010**;84(12):5936-5946.
22. Goldwasser J. *The grapefruit flavonoid naringenin as a hepatitis C virus therapy: Efficacy, mechanism and delivery.* [Ph. D.]. Massachusetts Institute of Technology; 2010.
23. Liu Y, Manchekar M, Sun Z, Richardson PE, Dashti N. Apolipoprotein B-containing lipoprotein assembly in microsomal triglyceride transfer protein-deficient McA-RH7777 cells. *J Lipid Res.* **2010**;51(8):2253-2264.
24. Wagoner J, Negash A, Kane OJ, et al. Multiple effects of silymarin on the hepatitis C virus lifecycle. *Hepatology.* **2010**;51(6):1912-1921.
25. Estellé J, Fernández A, Pérez-Enciso M, et al. A non-synonymous mutation in a conserved site of the MTTP gene is strongly associated with protein activity and fatty acid profile in pigs. *Anim Genet.* **2009**;40(6):813-820.
26. Greffhorst A, Parks EJ. Reduced insulin-mediated inhibition of VLDL secretion upon pharmacological activation of the liver X receptor in mice. *The Journal of Lipid Research.* **2009**;50(7):1374-1383.
27. Hernandez Vallejo SJ, Alqub M, Luquet S, et al. Short-term adaptation of postprandial lipoprotein secretion and intestinal gene expression to a high-fat diet. *Am J Physiol Gastrointest Liver Physiol.* **2009**;296(4):G782-92. doi: 10.1152/ajpgi.90324.2008.
28. Stewart BJ, Roede JR, Doorn JA, Petersen DR. Lipid aldehyde-mediated cross-linking of apolipoprotein B-100 inhibits secretion from HepG2 cells. *BBA-*

*Molecular and Cell Biology of Lipids*.  
**2009**;1791(8):772-780.

29. Begriche K, Massart J, Abbey-Toby A, Igoudjil A, Lettéron P, Fromenty B.  $\beta$ -Aminoisobutyric acid prevents diet-induced obesity in mice with partial leptin deficiency. *Obesity*. **2008**;16(9):2053-2067.
30. Begriche K, Letteron P, Abbey-Toby A, et al. Partial leptin deficiency favors diet-induced obesity and related metabolic disorders in mice. *Am J Physiol Endocrinol Metab*. **2008**;294(5):E939-51.
31. Chen Z, Newberry EP, Norris JY, et al. ApoB100 is required for increased VLDL-triglyceride secretion by microsomal triglyceride transfer protein in ob/ob mice. *J Lipid Res*. **2008**;49(9):2013-2022. doi: 10.1194/jlr.M800240-JLR200.
32. Li Y, Sugiyama E, Yokoyama S, Jiang L, Tanaka N, Aoyama T. Molecular mechanism of age-specific hepatic lipid accumulation in PPARalpha (+/-):LDLR (+/-) mice, an obese mouse model. *Lipids*. **2008**;43(4):301-312.
33. Lo CM, Nordskog BK, Nauli AM, et al. Why does the gut choose apolipoprotein B48 but not B100 for chylomicron formation? *American Journal of Physiology- Gastrointestinal and Liver Physiology*. **2008**;294(1):G344-G352.
34. Nahmias Y, Goldwasser J, Casali M, et al. Apolipoprotein B-dependent hepatitis C virus secretion is inhibited by the grapefruit flavonoid naringenin. *Hepatology*. **2008**;47(5):1437-1445.
35. Stafford JM, Yu F, Printz R, Hasty AH, Swift LL, Niswender KD. Central nervous system neuropeptide Y signaling modulates VLDL triglyceride secretion. *Diabetes*. **2008**;57(6):1482-1490.
36. Agarwal-Mawal A, Murray CM, Belkhome S, Cheema SK. Differential regulation of cholesterol homeostasis in transgenic mice expressing human cholesterol ester transfer protein. *Can J Physiol Pharmacol*. **2007**;85(3-4):430-438.
37. Castro J, Amigo L, Miquel JF, et al. Increased activity of hepatic microsomal triglyceride transfer protein and bile acid synthesis in gallstone disease. *Hepatology*. **2007**;45(5):1261-1266.
38. Cheema SK, Cornish ML. Bio F1B hamster: A unique animal model with reduced lipoprotein lipase activity to investigate nutrient mediated regulation of lipoprotein metabolism. *Nutr Metab (Lond)*. **2007**;4:27.
39. Kosone T, Takagi H, Horiguchi N, et al. HGF ameliorates a high-fat diet-induced fatty liver. *Am J Physiol Gastrointest Liver Physiol*. **2007**;293(1):G204-10.
40. Maiyoh GK, Kuh JE, Casaschi A, Theriault AG. Cruciferous indole-3-carbinol inhibits apolipoprotein B secretion in HepG2 cells. *J Nutr*. **2007**;137(10):2185-2189.
41. Bergheim I, Guo L, Davis MA, et al. Metformin prevents alcohol-induced liver injury in the mouse: Critical role of plasminogen activator inhibitor-1. *Gastroenterology*. **2006**;130(7):2099-2112.
42. Briand F, Serisier S, Krempf M, et al. Atorvastatin increases intestinal cholesterol absorption in dogs. *J Nutr*. **2006**;136(7 Suppl):2034S-2036S.
43. Lambert G, Jarnoux AL, Pineau T, et al. Fasting induces hyperlipidemia in mice overexpressing proprotein convertase subtilisin kexin type 9: Lack of modulation of very-low-density lipoprotein hepatic output by the low-density lipoprotein receptor. *Endocrinology*. **2006**;147(10):4985-4995.
44. Li L, Stillemark-Billton P, Beck C, et al. Epigallocatechin gallate increases the formation of cytosolic lipid droplets and decreases the secretion of apoB-100 VLDL. *J Lipid Res*. **2006**;47(1):67-77. doi: 10.1194/jlr.M500424-JLR200.
45. PAUQUAI T, BOUCHOUX J, CHATEAU D, et al. Adaptation of enterocytic caco-2 cells to glucose modulates triacylglycerol-rich lipoprotein secretion through triacylglycerol targeting into the endoplasmic reticulum lumen. *Biochem J*. **2006**;395:393-403.
46. Ameen C, Edvardsson U, Ljungberg A, et al. Activation of peroxisome proliferator-activated receptor alpha increases the expression and activity of microsomal triglyceride transfer protein in the liver. *J Biol Chem*. **2005**;280(2):1224-1229.
47. Domitrovich AM, Felmlee DJ, Siddiqui A. Hepatitis C virus nonstructural proteins inhibit apolipoprotein B100 secretion. *J Biol Chem*. **2005**;280(48):39802-39808.
48. Lewis GF, Uffelman K, Naples M, Szeto L, Haidari M, Adeli K. Intestinal lipoprotein overproduction, a newly recognized component of insulin resistance, is ameliorated by the insulin sensitizer rosiglitazone: Studies in the fructose-fed syrian golden hamster. *Endocrinology*. **2005**;146(1):247-255.
49. Qiu W, Taghibiglou C, Avramoglu RK, et al. Oleate-mediated stimulation of microsomal triglyceride transfer protein (MTP) gene promoter: Implications for hepatic MTP overexpression in insulin resistance†. *Biochemistry (N Y)*. **2005**;44(8):3041-3049.
50. Vidal R, Hernandez-Vallejo S, Pauquai T, et al. Apple procyanidins decrease cholesterol esterification and lipoprotein secretion in caco-2/TC7 enterocytes. *J Lipid Res*. **2005**;46(2):258-268.
51. Casaschi A, Maiyoh GK, Rubio BK, Li RW, Adeli K, Theriault AG. The chalcone xanthohumol inhibits triglyceride and apolipoprotein B secretion in HepG2 cells. *J Nutr*. **2004**;134(6):1340-1346.
52. Casaschi A, Rubio BK, Maiyoh GK, Theriault AG. Inhibitory activity of diacylglycerol acyltransferase (DGAT) and microsomal triglyceride transfer protein (MTP) by the flavonoid, taxifolin, in HepG2 cells: Potential role in the regulation of apolipoprotein B secretion. *Atherosclerosis*. **2004**;176(2):247-253.
53. Kurowska EM, Manthey JA, Casaschi A, Theriault AG. Modulation of HepG2 cell net apolipoprotein B secretion by the citrus polymethoxyflavone, tangeretin. *Lipids*. **2004**;39(2):143-151.
54. Aoki T, Yamazaki H, Tamaki T, Sato F, Kitahara M, Saito Y. Triglyceride-lowering effect of pitavastatin in a guinea pig model of postprandial lipemia. *Arzneimittelforschung*. **2003**;53(03):154-158.
55. Higashi Y, Itabe H, Fukase H, Mori M, Fujimoto Y, Takano T. Transmembrane lipid transfer is crucial for providing neutral lipids during very low density lipoprotein assembly in endoplasmic reticulum. *J Biol Chem*. **2003**;278(24):21450-21458.
56. Letteron P, Sutton A, Mansouri A, Fromenty B, Pessayre D. Inhibition of microsomal triglyceride transfer protein: Another mechanism for drug-induced steatosis in mice. *Hepatology*. **2003**;38(1):133-140.

57. Casaschi A, Wang Q, Dang K, Richards A, Theriault A. Intestinal apolipoprotein B secretion is inhibited by the flavonoid quercetin: Potential role of microsomal triglyceride transfer protein and diacylglycerol acyltransferase. *Lipids*. **2002**;37(7):647-652.
58. Perlemuter G, Sabile A, Letteron P, et al. Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: A model of viral-related steatosis. *FASEB J*. **2002**;16(2):185-194.
59. Taguchi H, Omachi T, Nagao T, Matsuo N, Tokimitsu I, Itakura H. Dietary diacylglycerol suppresses high fat diet-induced hepatic fat accumulation and microsomal triacylglycerol transfer protein activity in rats. *J Nutr Biochem*. **2002**;13(11):678-683.
60. Fisher EA, Pan M, Chen X, et al. The triple threat to nascent apolipoprotein B. evidence for multiple, distinct degradative pathways. *J Biol Chem*. **2001**;276(30):27855-27863.
61. Funatsu T, Suzuki K, Goto M, et al. Prolonged inhibition of cholesterol synthesis by atorvastatin inhibits apo B-100 and triglyceride secretion from HepG2 cells. *Atherosclerosis*. **2001**;157(1):107-115.
62. Jin FY, Kamanna VS, Kashyap ML. Niacin accelerates intracellular ApoB degradation by inhibiting triacylglycerol synthesis in human hepatoblastoma (HepG2) cells. *Arterioscler Thromb Vasc Biol*. **1999**;19(4):1051-1059.